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Background: Stereotactic body radiation therapy (SBRT) delivers high doses of radiation to the prostate while
minimizing radiation to adjacent normal tissues. Large fraction sizes may increase the risk of functional decrements.
Treatment-related bother may be more important to a patient than treatment-related dysfunction. This study
reports on patient-reported outcomes following SBRT for clinically localized prostate cancer.
Methods: Between August 2007 and July 2011, 228 consecutive hormone-naïve patients with clinically localized
prostate cancer were treated with 35–36.25 Gy SBRT delivered using the CyberKnife Radiosurgical System (Accuray)
in 5 fractions. Quality of life was assessed using the American Urological Association Symptom Score (AUA) and the
Expanded Prostate Cancer Index Composite (EPIC)-26. Urinary symptom flare was defined as an AUA score 15 or
more with an increase of 5 or more points above baseline 6 months after treatment.
Results: 228 patients (88 low-, 126 intermediate- and 14 high-risk) at a median age of 69 (44–90) years received
SBRT with a minimum follow-up of 24 months. EPIC urinary and bowel summary scores declined transiently at
1 month and experienced a second, more protracted decline between 9 months and 18 months before returning
to near baseline 2 years post-SBRT. 14.5% of patients experienced late urinary symptom flare following treatment.
Patients who experienced urinary symptom flare had poorer bowel quality of life following SBRT. EPIC scores for
urinary bother declined transiently, first at 1 month and again at 12 months, before approaching pre-treatment
scores by 2 years. Bowel bother showed a similar pattern, but the second decline was smaller and lasted 9 months
to 18 months. EPIC sexual summary and bother scores progressively declined over the 2 years following SBRT
without recovery.
Conclusions: In the first 2 years, the impact of SBRT on urination and defecation was minimal. Transient late
increases in urinary and bowel dysfunction and bother were observed. However, urinary and bowel function and
bother recovered to near baseline by 2 years post-SBRT. Sexual dysfunction and bother steadily increased following
treatment without recovery. SBRT for clinically localized prostate cancer was well tolerated with treatment-related
dysfunction and bother comparable to conventionally fractionated radiation therapy or brachytherapy.
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Stereotactic body radiation therapy (SBRT) is establishing
itself as a new modality for the treatment of clinically lo-
calized prostate cancer [1,2]. SBRT delivers high doses of
radiation to target volumes with precision while minimiz-
ing radiation exposure to adjacent healthy tissues [3,4].
With SBRT, biochemical disease-free survival is high [5]
while toxicity has been comparable to conventionally frac-
tionated radiation therapy despite higher doses per frac-
tion [5-8]. Presently, there is limited data suggesting that
any particular treatment for prostate cancer has superior
outcomes compared to the others [9]. As a result, the
choice of intervention is guided by the treatment’s side ef-
fect profile and the patient’s subsequent health-related
quality of life (HRQOL) [10].
Commonly employed prostate cancer-specific quality of
life (QOL) questionnaires contain questions that assess
both function and bother (the annoyance that patients ex-
perience due to functional decrements) [11,12]. Several
studies have assessed QOL outcomes following SBRT for
clinically localized prostate cancer [2,5,13]. These studies
have primarily focused on functional decrements following
treatment. Bother, a subjective measure of QOL, may be
more important to an individual patient than treatment-
related dysfunction. While function and bother share an
association, it varies across specific domains [14]. Even
within a given domain, function and bother may vary over
time [10-12]. With time, patients may come to accept
functional deficits and become less bothered by them
[11,12,15,16]. Bother may be more affected by the patient’s
expectations prior to treatment rather than the severity of
the functional decrement [12,17,18].
Limited data to date is available on patient-reported out-
comes following SBRT. Further knowledge in this area
would facilitate better communication between patients
and physicians when deciding on the appropriate manage-
ment route. The objective of this study is to report the
urinary, bowel, and sexual QOL outcomes following SBRT
in patients with clinically localized prostate cancer.
Methods
Patient selection
Patients eligible for study inclusion had histologically-
confirmed adenocarcinoma of the prostate treated per
our institutional protocol. Patients who received ADT
were excluded from this study due to its known adverse
effects on patient-reported outcomes [19]. Georgetown
University Institutional Review Board approval was ob-
tained for retrospective review of data that was prospect-
ively collected in our institutional database.
SBRT treatment planning and delivery
SBRT treatment planning and delivery was performed as
previously described [4,7]. Gold fiducials were placedinto the prostate using ultrasound guidance. Fused thin
cut CT images and high-resolution MR images were
used for treatment planning. The clinical target volume
(CTV) included the prostate and proximal seminal vesi-
cles. The planning target volume (PTV) included a 5 mm
anterolateral expansion and a 3 mm posterior expansion
around the CTV. A prescription dose of 35–36.25 Gy was
delivered to the PTV in 5 fractions of 7–7.25 Gy over 1–
2 weeks. The bladder, membranous urethra, rectum, and
penile bulb were contoured and evaluated with dose-
volume histogram analysis during treatment planning.
Target position was confirmed multiple times during
each treatment with a minimum of 3 properly-placed fi-
ducials [4].
Follow-up and statistical analysis
Patients completed the Expanded Prostate Cancer Index
Composite (EPIC)-26 [20], American Urological Associ-
ation Symptom Index (AUA) [21], and Sexual Health
Inventory for Men (SHIM) questionnaires [22] before
treatment and during routine follow-up visits 1 month
after the completion of SBRT, every 3 months for the
first year, and then every 6 months for the second year.
The EPIC-26 is a validated tool that measures urinary,
bowel, and sexual function and bother [20]. To statisti-
cally compare changes between time points, the levels of
responses were assigned a score, and the significance of
the mean changes in the scores was assessed by paired
t-test. Responses to the EPIC-26 questionnaire were
grouped by physiologic domains and assigned numerical
scores. The multi-item scale scores were transformed
linearly to a 0–100 scale as recommended in the scoring
instructions for the EPIC-26. Lower numbers corre-
sponded to worsening function and increased bother. For
the overall urinary, bowel, and sexual bother questions
(Questions 5, 7, and 12), the responses were grouped into
3 clinically relevant categories (no problem, very-small to
small problem, and moderate to big problem). Wilcoxon
Signed-Rank Test and chi-square analysis were used to as-
sess differences in QOL scores in comparison to baseline.
Paired t-test was used to assess the significance of the
change in scores. The minimally important difference
(MID) to assess for clinically significant change in HRQOL
from baseline was set as half a standard deviation (SD)
[23]. As previously reported, late urinary symptom flare
was defined as an increase of ≥ 5 points above baseline with
a degree of severity in the moderate to severe range (AUA
score ≥ 15) [7,24]. Statistical analysis was limited to time
points with a ≥ 80% response rate to limit the effect of attri-
tion bias.
Results
From August 2007 to July 2011, 228 hormone-naïve pa-
tients with clinically localized prostate adenocarcinoma





≥ 20 (Severe) 3.5%
Baseline SHIM score
22-25 (No ED) 23.8%
17-21 (Mild ED) 22.9%
12-16 (Mild-Moderate ED) 13.9%
8-11 (Moderate ED) 5.4%
< 8 (Severe ED) 34.1%
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protocol. The patients were followed for a minimum of
24 months following SBRT. The median patient age was
69 (44–90) years old (Table 1). 58.8% patients were
white, and 35.5% were black. 75.4% patients had part-
ners, and 47.4% patients were employed. 38.6% patients
were low-risk, 55.3% patients were intermediate-risk,
and 6.1% patients were high-risk. The median prostate
volume was 37.3 (11.6-138.7) cc. 48% of patients had
moderate to severe lower urinary tract symptoms prior
to treatment (baseline AUA ≥ 8) with a median baseline
AUA of 7 (Table 2). The median pre-treatment testoster-
one was 11 (3.99-39.87) nmol/L. 77.2% of patients had
erectile dysfunction prior to treatment (baseline SHIM ≤
21) with a median baseline SHIM of 16 (Table 2). 38.1%
of patients utilized sexual aids prior to SBRT.Table 1 Patient characteristics
Patients
(N = 228)
Age (y/o) (Median = 69)
Age≤ 60 11.0%
60 < Ages≤ 70 45.6%




























Baseline EPIC-26 summary score Mean SD MID
Urinary domain 89.6 10.92 5.5
Bowel domain 95.1 8.55 4.3
Sexual domain 56.3 28.92 14.5
Baseline EPIC-26 bother score Mean SD MID
Urinary domain 80.2 24.45 12.2
Bowel domain 91.4 18.49 9.2
Sexual domain 65.9 34.49 17.2
Abbreviation: AUA American Urological Association symptom scores,
SHIM Sexual Health Inventory for Men, EPIC Expanded Prostate Cancer Index
Composite, SD Standard Deviation, MID Minimally Important Difference.84% of patients were treated with 36.25 Gy in five
7.25 Gy fractions (Table 1). The median follow-up was
3.8 years. The median pre-treatment PSA of 6.1 ng/ml de-
clined by two years post-treatment to a median PSA of
0.49 ng/ml. There were 6 biochemical failures, occurring
in 1 low-risk patient, 3 intermediate-risk patients, and 2
high-risk patients. The overall 2-year actuarial biochemical
relapse-free survival was 97.2%. No patients received an-
drogen deprivation therapy at any time during the first
2 years following SBRT.
Baseline EPIC summary scores are shown in Table 2 and
mean changes in EPIC summary scores from baseline to
2 years of follow-up are shown in Table 3. The EPIC urin-
ary summary score declined transiently at 1 month post-
SBRT (mean change from baseline, -7.6) (Table 3) and
returned to near baseline by 3 months post-SBRT (mean
change from baseline, -1.5) (Table 3, Figure 1a). This acute
decline was both statistically (p < 0.0001) and clinically sig-
nificant (MID = 5.5). A second late, protracted decline oc-
curred between 9 months and 18 months (mean change
from baseline at 12 months, -5.1) (Table 3). Transient late
urinary symptom flare (≥ 6 months after completing treat-
ment) occurred in 14.5% of the patients (Figure 1b) [7].
The median flare magnitude was 14 (5–30) and the median












SD P Mean score
change from
baseline
SD P Mean score
change from
baseline




Urinary summary −7.6 13.2 <0.0001 −1.5 11.9 0.0769 −5.1 14.9 <0.0001 −2.6 14.8 0.0135
Bowel summary −10.1 17.7 <0.0001 −3.1 11.4 0.0002 −3.4 11.7 <0.0001 −1.4 9.8 0.0512
Sexual summary −5.7 29.5 <0.0001 −4.2 30.9 0.0007 −9.2 30.4 <0.0001 −11.8 30.8 <0.0001
Bhattasali et al. Radiation Oncology 2014, 9:52 Page 4 of 10
http://www.ro-journal.com/content/9/1/52time to flare was 12 (6–24) months. The EPIC urinary sum-
mary score returned to near baseline by 2 years post-SBRT
(mean change from baseline, -2.6) (Table 3, Figure 1a).
Likewise, the EPIC bowel summary score declined
transiently at 1 month (mean change, -10.1) (Table 3)
and experienced a second, more protracted decline be-
tween 9 months and 18 months (mean change from
baseline at 12 months, -3.4). Bowel declines at 1 month
and 12 months were statistically significant (p < 0.0001);
however, only the change at 1 month met the threshold
for clinically significant change (MID = 4.3) (Figure 2a).
Transient late declines in the EPIC bowel summary do-
main were more common in patients who experienced
late urinary symptom flare (Figure 2b). The EPIC bowel
summary score returned to near baseline at 2 years
post-SBRT (mean change from baseline, -1.4) (Table 3,
Figure 2a).
The EPIC sexual summary score progressively declined
over 24 months (Figure 3). Sexual declines were statisti-
cally significant (p < 0.001) at all follow-ups, but the re-
sults were not found to be clinically significant due to
the high variation in baseline sexual function [25] andFigure 1 Urinary function. (a) EPIC urinary summary domain scores at ba
significant changes in scores (½ standard deviation above and below the b
with higher values representing a more favorable health-related QOL. (b) Pconsequent EPIC sexual summary score in the study
population (MID = 14.5) (Table 2).
Treatment-related bother may be more important to
an individual patient than treatment-related dysfunction.
At baseline, nearly half (49.6%) of our cohort reported
some level of annoyance due to urinary symptoms with
8.0% of the patients feeling that urination was a moder-
ate to big problem (Table 4, Figure 4a). Baseline EPIC
bother scores are shown in Table 2 and mean changes in
EPIC bother scores from baseline to 2 years of follow-up
are shown in Table 5. The mean EPIC urinary bother
score was 80.2 at baseline (Table 2). Urinary bother in-
creased following treatment with the mean score decreas-
ing to 68.2 at 1 month post-treatment (mean change, -12)
(p < 0.0001) (Table 5, Figure 4b). However, only 14.6% of
patients felt that urination was a moderate to big problem
at 1 month following treatment (Table 4, Figure 4a). Al-
though urinary bother declined quickly, a second late in-
crease in urinary bother was observed with the mean
urinary bother score decreasing to 71.2 at 12 months
(mean change from baseline, -9) (p = 0.0009) (Figure 4b).
Only the first decline approached the threshold forseline and following SBRT for prostate cancer. Thresholds for clinically
aseline) are marked with dashed lines. EPIC scores range from 0–100
ercentage of patients with urinary symptom flare at each follow-up.
Figure 2 Bowel function. (a) EPIC bowel summary domain scores at baseline and following SBRT for prostate cancer. (b) EPIC bowel summary
domain scores in patients with or without urinary symptom flare. Thresholds for clinically significant changes in scores (½ standard deviation
above and below the baseline) are marked with dashed lines. EPIC scores range from 0–100 with higher values representing a more favorable
health-related QOL.
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of patients felt that urination was a moderate to big prob-
lem at 12 months following treatment (Table 4, Figure 4a).
By two years following SBRT, urinary bother returned to
near baseline with a urinary bother score of 78.3 (mean
change from baseline, -1.9) and 8.1% of patients feeling
that urination was a moderate to big problem (Table 4,
Figure 4a).
Bowel bother showed a similar pattern as urinary bother,
but the second increase in the bowel bother score was
smaller and lasted 9 months to 18 months (Table 4,Figure 3 Sexual function. EPIC sexual summary domain scores at baseline
significant changes in scores (½ standard deviation above and below the b
with higher values representing a more favorable health-related QOL.Figure 5). At baseline, 23.0% of patients reported some
level of annoyance due to bowel symptoms with 3.5% of
patients feeling that bowel function was a moderate to big
problem (Table 4, Figure 5a). The mean EPIC bowel bother
score was 91.4 at baseline (Table 2). Bowel bother wors-
ened post-treatment, and the mean score decreased to 76.0
at 1 month (mean change, -15.4) (p < 0.0001) (Table 5,
Figure 5b). However, only 11% of patients felt that their
bowel function was a moderate to big problem at 1 month
following SBRT (Table 4, Figure 5a). Bowel bother scores
worsened over a second, more protracted time periodand following SBRT for prostate cancer. Thresholds for clinically
aseline) are marked with dashed lines. EPIC scores range from 0–100
Table 4 EPIC bothers
Start 1 Mon 3 Mon 6 Mon 9 Mon 12 Mon 18 Mon 24 Mon
Total N 226 219 215 213 212 210 193 197
Urinary bother
No problem 50.4% 25.6% 41.4% 45.1% 42.5% 36.7% 46.6% 45.2%
Very small-small problem 41.6% 59.8% 52.6% 46.5% 44.8% 48.1% 40.4% 46.7%
Moderate-big problem 8.0% 14.6% 6.0% 8.5% 12.7% 15.2% 13.0% 8.1%
p= <0.0001 0.0009
Bowel bother
No problem 77.0% 44.3% 66.5% 68.5% 63.2% 63.3% 66.1% 72.1%
Very small-small problem 19.5% 44.7% 30.2% 28.2% 31.6% 30.0% 29.7% 25.4%
Moderate-big problem 3.5% 11.0% 3.3% 3.3% 5.2% 6.7% 4.2% 2.5%
p= <0.0001 0.0017 0.001 0.0408
Sexual bother
No problem 39.4% 37.0% 36.4% 39.0% 37.9% 40.3% 36.3% 36.2%
Very small-small problem 36.3% 35.2% 37.9% 31.0% 30.3% 32.2% 29.5% 29.1%
Moderate-big problem 24.3% 27.9% 25.7% 30.0% 31.8% 27.5% 34.2% 34.7%
p= 0.0022 0.0037
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scores included 85.8 at 9 months (p = 0.0017), 85.8 at
12 months (mean change from baseline, -5.7) (p = 0.001)
(Table 5), and 87.8 at 18 months (p = 0.041) (Figure 5b).
Once again, only the first decline met the threshold for
clinically significant change (MID = 9.2). Only 6.7% of
patients felt that bowel symptoms were a moderate to
big problem at 12 months following treatment (Table 4,
Figure 5a). Once again, transient late declines in theFigure 4 EPIC urinary bother at baseline and following SBRT for pros
no problem, very small-small problem, and moderate-big problem. (b) Ave
Thresholds for clinically significant changes in scores (½ standard deviation
EPIC scores range from 0–100 with higher values representing a more favoEPIC bowel bother score were more common in patients
who experienced late urinary symptom flare (Figure 5c).
By 2 years following SBRT, bowel bother returned to near
baseline with a bowel bother score of 90.6 (mean change
from baseline, -0.8) (Table 5) and 2.5% of patients feeling
bowel symptoms were a moderate to big problem (Table 4,
Figure 5a).
Sexual bother slowly increased over the first 24 months
following SBRT without recovery (Table 4, Figure 6).tate cancer. (a) Urinary bother was stratified to three levels of bother:
rage overall urinary bother scores (Question 5 of the EPIC-26).
above and below the baseline) are marked with dashed lines.
rable health-related QOL.












SD P Mean score
change from
baseline
SD P Mean score
change from
baseline




Urinary bother −12 26 <0.0001 −0.4 21.6 0.8182 −9 29.8 0.0009 −1.9 25.8 0.773
Bowel bother −15.4 26.7 <0.0001 −3.6 20.1 0.0719 −5.7 23 0.001 −0.8 18.1 0.984
Sexual bother −2.5 35.3 0.24 −1.1 34.3 0.563 −2.7 36.9 0.097 −7.5 37.8 0.0037
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baseline with 24.3% of the patients feeling that sex was a
moderate to big problem (Table 4, Figure 6a). Worsening
of sexual bother was statistically significant at 18 months
(p = 0.0022) and 24 months (p = 0.0037) (Figure 6b). MeanFigure 5 EPIC bowel bother at baseline and following SBRT for prosta
problem, very small-small problem, and moderate-big problem. (b) Averag
bowel bother scores in patients with or without urinary symptom flare. Thr
above and below the baseline) are marked with dashed lines. EPIC scores r
health-related QOL.EPIC sexual bother scores progressively declined from
65.9 at baseline to 58.4 by the end of the study (mean
change from baseline, -7.5) (Table 5, Figure 6b). The re-
sults were not found to be clinically significant due to the
high variation in the EPIC sexual bother score in the studyte cancer. (a) Bowel bother was stratified to three levels of bother: no
e overall bowel bother scores (Question 7 of the EPIC 26). (c) EPIC
esholds for clinically significant changes in scores (½ standard deviation
ange from 0–100 with higher values representing a more favorable
Figure 6 EPIC sexual bother at baseline and following SBRT for prostate cancer. (a) Sexual bother was stratified to three levels of bother:
no problem, very small-small problem, and moderate-big problem. (b) Average overall sexual bother scores (Question 12 of the EPIC 26).
Thresholds for clinically significant changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC
scores range from 0–100 with higher values representing a more favorable health-related QOL.
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sexual bother was a moderate-big problem by 24 months
post-SBRT (Table 4, Figure 6a).
Discussion
Post-treatment urinary, bowel, and sexual outcomes are
important considerations in the management of clinic-
ally localized prostate cancer. Because SBRT is a newer
management option for prostate cancer, there is limited
data regarding outcomes after therapy. Our prior work
focused on functional decrements following treatment
[1,2]. Bother may be more important to an individual pa-
tient than treatment-related dysfunction. Further know-
ledge in this area would facilitate better communication
between patients and physicians when deciding on the ap-
propriate management route. Understanding the risk of
dysfunction prior to beginning treatment may alleviate
bother related to dysfunction. This study assessed patient-
reported urinary, bowel, and sexual function and associ-
ated bother following SBRT.
Although SBRT delivers highly precise doses, there is un-
avoidable dose to the bladder neck and urethra that may
cause urinary dysfunction and bother. Moderate to severe
urinary bother increased following SBRT from a baseline of
8% to 15% 1 month following treatment. This compares fa-
vorably to the 30-39% of patients who report acute moder-
ate to severe urinary bother following alternative radiation
modalities [10]. As seen with conventionally fractionated
external beam radiation therapy [10], this increase in urin-
ary bother was transient and returned to baseline by
3 months post-SBRT. Similar to brachytherapy [10], a sec-
ond increase in urinary bother occurred 12 months post-
SBRT with 15% of patients reporting moderate to severe
bother at that time point. This late bother may be associ-
ated with the phenomenon of urinary symptom flare[7,24,26,27]. Unlike brachytherapy, urinary bother returned
to near baseline by 2 years post-SBRT [10,24,26,27]. Bother
may have exceeded its associated dysfunction due to an
unexpected increase in urinary symptoms occurring
months after the expected early symptoms had already
resolved. Patient counseling regarding urinary symptom
flare may minimize increased urinary bother 1 year fol-
lowing SBRT.
Bowel bother following SBRT showed a similar pattern
as urinary bother. Moderate to severe bowel bother
increased following SBRT from a baseline of 3.5% to 11%
1 month following SBRT. This compares favorably to
the 15-16% of patients who report acute moderate to se-
vere bowel bother following alternative radiation modal-
ities [10,28]. Unlike alternative modalities, this increase
in bowel bother was transient and returned to near base-
line by 3 months post-SBRT [10,28]. A second gradual
increase in bowel bother occurred from 9 months to
18 months with approximately 7% of patients reporting
moderate to severe bowel bother at 12 months. Similar to
urinary bother, post-SBRT bowel bother returned to near
baseline by 2 years post-SBRT.
Increased rates of bowel toxicity have been previously
described in patients who experienced urinary symptom
flare following brachytherapy [27]. To our knowledge,
this is the first report showing an association between
late urinary symptom flare and increased late bowel dys-
function and bother following SBRT. The etiology of this
association is unclear but could be related to the close
proximity of the involved organs [29] or due to the in-
herent increased radiation sensitivity in patients who ex-
perience urinary symptom flare [27,30].
Sexual bother demonstrated the poorest outcomes
among all domains. As seen by others [25], a large pro-
portion of our patients had erectile dysfunction prior to
Bhattasali et al. Radiation Oncology 2014, 9:52 Page 9 of 10
http://www.ro-journal.com/content/9/1/52treatment. Moderate to severe sexual bother progres-
sively increased from 24% at baseline to 35% by 2 years
post-SBRT. While a small portion of the decline may be
attributed to increasing age and the natural progression
of erectile dysfunction, it is unlikely that age would be
the sole reason for this decline. Multiple sexual aids exist
to improve sexual function and may alleviate bother [31].
Patients may benefit from education regarding these avail-
able and effective enhancement tools.
Although the results of this study are promising, there
remains uncertainty and a lack of data regarding longer-
term toxicity from SBRT. Given the resolution of urinary
and bowel toxicity by 2 years, the likelihood of a resur-
gence of symptoms remains low. Definitive conclusions
will require the analysis of longer-term follow-up.
Conclusions
SBRT for clinically localized prostate cancer was well tol-
erated with treatment-related function and bother com-
parable to alternative treatments [10,32]. Patients reported
urinary and bowel problems at 1 month that returned to
baseline by 24 months. Bothersome late urinary and bowel
symptoms presented transiently between 9–18 months
post-SBRT but resolved by 2 years. Sexual function and
bother decreased progressively over 24 months. Educating
patients regarding both the acute and delayed effects of
SBRT and addressing expectations prior to treatment may
decrease bother.
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